Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 3 1Phase 2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Nasopharyngeal Carcinoma 3Esophageal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Spinocerebellar Degenerations 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Nasopharyngeal Cancinoma (NPC) 1Melanoma 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Hepatocellular 1Anus Neoplasms 1Anal Canal Carcinoma 1

Interventions

Paclitaxel 23Carboplatin 22Capecitabine 18Gemcitabine 16130-nm albumin-bound paclitaxel 16pembrolizumab 14Cyclophosphamide 12atezolizumab 9Epirubicin 9sacituzumab govitecan 8Albumin-Bound Paclitaxel 8eribulin 6Vinorelbine 6Drug Therapy 6Doxorubicin 6camrelizumab 4Docetaxel 4Cisplatin 4Injections 3pegfilgrastim 2olaparib 2famitinib 2Filgrastim 2Everolimus 2veliparib 1trilaciclib 1toripalimab 1taxane 1niraparib 1ipatasertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Triple Negative Breast Neoplasms × Immune Checkpoint Inhibitors × Clear all
NCT06627712 2026-01-30

SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC

West China Hospital

Phase 3 Recruiting
318 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡